On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug ...

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

In a statement, Avadel acknowledged that it had received the Lundbeck bid and that its board of directors had "determined in ...

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making ...

This World Diabetes Day, Sanofi UK and DigiBete are hosting a pop-up event in Leeds today and tomorrow, 14th & 15th November, ...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas, about ...

Alkermes already has positive results for alixorexton in NT1 from the phase 2 Vibrance-1, while Takeda is developing another ...

The $6.7 billion merger brought together two companies that had been forced to file for bankruptcy protection due to opioid ...

The growth of the stronger product – which now accounts for more than a quarter of Eylea sales – allowed Bayer to predict ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

Eisai has already reached settlement agreements with two other companies seeking to market Lenvima generics in the US – Sun ...